You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

49 Results
Guidelines and Advice
Status: Archived
ID: DAP
Jun 2007
Guidelines and Advice
Status: Archived
ID: CED 6
Jun 2007
Guidelines and Advice
Status: Archived
ID: CED 5
May 2007
Guidelines and Advice
Status: Archived
ID: CED 4
May 2007
Guidelines and Advice
Status: Archived
ID: 4-14
Oct 2007
Guidelines and Advice
Status: Archived
ID: 7-1-2N
Dec 2007
Guidelines and Advice
Status: Archived
ID: 6-19
Jan 2007
Guidelines and Advice
Status: Archived
ID: 6-22
Jan 2007
Guidelines and Advice
Status: Education and Information
ID: 15-1
Jun 2007
Statistical Reports
Oct 2007
Guidelines and Advice
Jan 2007
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages